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Abstract
Bacterial pathogens possess an array of specific mechanisms that
confer virulence and the capacity to avoid host defence mecha-
nisms. Mechanisms of virulence are often mediated by the sub-
version of normal aspects of host biology. In this way the pathogen
modifies host function so as to promote the pathogen’s survival or
proliferation. Such subversion is often mediated by the specific
interaction of bacterial effector molecules with host encoded
proteins and other molecules. The importance of these mechanisms
for bacterial pathogens that cause infections leading to severe
community-acquired infections is well established. In contrast, the
importance of specialised mechanisms of virulence in the genesis of
nosocomial bacterial infections, which occur in the context of local
or systemic defects in host immune defences, is less well
established. Specific mechanisms of bacterial resistance to host
immunity might represent targets for therapeutic intervention. The
clinical utility of such an approach for either prevention or treatment
of bacterial infection, however, has not been determined.
Introduction
The interaction of pathogenic bacteria with the host plays a
central role in many forms of critical illness. As well as being a
common trigger of sepsis that necessitates admission to the
intensive care unit (ICU), bacterial infections are responsible
for the majority of nosocomial infections that occur in these
patients.
For over 60 years the mainstay of treatment of bacterial
infection has been antibiotics. There is overwhelming
evidence, albeit derived from observational studies, that
administration of antibiotics improves survival of patients with
severe sepsis [1]. Antibiotic treatment, however, is often not
sufficient to improve mortality [2]. Although the prophylactic
use of antibiotics can reduce nosocomial infection, the
practice remains controversial and it cannot eliminate noso-
comial infection [3]. Of substantial concern is the increasing
problem of antibiotic resistance – a problem that ICUs both
contribute to as well as suffer from [4]. Despite the rising
incidence of antibiotic resistance in many bacterial patho-
gens, interest in antibiotic drug discovery by commercial
entities is in decline [5].
Bacterial virulence is ‘the ability to enter into, replicate within,
and persist at host sites that are inaccessible to commensal
species’ [6]. As a consequence of the availability of whole
genome sequencing and high-throughput techniques for the
identification of virulence genes from many bacterial
pathogens, the past 10 to 15 years have witnessed a revolu-
tion in the understanding of bacterial virulence. While
virulence factors such as capsules and serum resistance
have been known for decades, and are often necessary if not
sufficient for infection, a much wider array of more specialised
determinants of virulence has now been characterised. Many
of these mechanisms of virulence are now defined at precise
molecular and genetic levels; however, the ultimate clinical
relevance of this knowledge remains uncertain. With the
possible exception of lincosamides, such as clindamycin, all
existing antibiotics target bacterial products that are essential
for survival of the organism, leading to bacterial death, and do
not target mechanisms of virulence. Whether virulence will
ever be a useful and drugable target remains speculative but,
in the presence of increasing antibiotic resistance and
decreasing antibiotic drug development, it is a potentially
important question.
Principles of bacterial virulence
Although encounters between bacteria and humans occur
continuously, the establishment of infection after such
contact is extremely rare. The ability of the human body to
prevent most interactions with bacteria resulting in harm is a
testament to the multilayered defences that prevent the
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establishment of bacterial infection. The most effective of
these defences are the barrier function of epithelial surfaces
and innate immune responses – both of which are deeply
evolutionarily conserved [7].
Just as humans possess sophisticated and effective defences
against infection, the bacteria that are capable of infection
possess equally sophisticated mechanisms to counteract and
overcome the human defences allayed against them. The core
competencies of a potentially pathogenic bacterium are to gain
access to the body; to attain a unique niche; to avoid, subvert
or circumvent innate host defences; to evade acquired specific
immune responses; to acquire necessary nutrients; to multiply
or persist; to cause tissue damage or disease; and to exit and
transmit infection to new hosts [8]. Pathogenic bacteria
possess specific mechanisms to achieve each of these aims,
and it is the possession of these mechanisms that distin-
guishes pathogenic bacteria from nonpathogens. These
mechanisms of virulence are genetically encoded by so-called
virulence genes, and possession of such genes distinguishes
pathogenic bacteria from nonpathogens. There is a spectrum
of pathogenic potential among pathogenic bacteria – from
those that are opportunistic pathogens, only capable of virulent
behaviour in the presence of local or systemic defects of host
defences, through to pathogens, which might be termed
professional, capable of pathogenic behaviour in the presence
of normally functioning host defences. Within broad limits the
latter are much more responsible for severe infection that
necessitates ICU admission, with clear attributable mortality. In
contrast, the virulence and harm caused to the host by bacteria
that cause nosocomial infection is an open question.
There is little work that compares virulence – for example, by
evaluation of the lethal dose in animal models – of noso-
comial versus community-acquired pathogens. The presence
of invasive devices is important in the genesis of nosocomial
infections in the ICU, suggesting that local defects in host
defence contribute to infection [9]. Furthermore, and while
nosocomial infections are of major clinical importance, their
harm, in terms of mortality, has not been well defined.
Unadjusted studies show an association between the
occurrence of ventilator-associated pneumonia and mortality.
After adjustment for factors that independently influence the
occurrence of ventilator-associated pneumonia and death,
such as severity and progression of underlying illness,
however, an independent effect on mortality has not been
demonstrated in several large studies [10-12].
The contribution of a gene to bacterial virulence is defined by
the molecular Koch’s postulates [13]. It is not necessary to
fulfil all postulates but a gene is more likely to contribute to
virulence if it is present in pathogens but absent from closely
related nonpathogenic organisms, if inactivation of the gene
(via genetic engineering) results in loss of a virulent pheno-
type, and if replacement by an intact copy of the inactivated
gene results in restoration of virulence [13]. Within the
bacterial genome, virulence genes are often organised
together in contiguous regions known as pathogenicity
islands [14]. These packages often contain a set of genes,
the products of which contribute to a specific virulence
function, such as a type III secretion system (T3SS). Bacteria,
unlike higher organisms, can transfer genetic material within
and across species boundaries by horizontal transfer. Patho-
genicity islands that contain similar genes and serve the same
function have been identified in pathogens that have no
recent common ancestor. This capacity for horizontal gene
transfer is responsible for the wide and rapid spread of anti-
biotic resistance genes but has also served, over a longer
evolutionary time period, to spread common mechanisms of
virulence amongst diverse pathogens. Bacterial genes that
contribute to virulence are often not expressed constitutively
but rather are induced only following contact with or invasion
of a host [15]. The expression of such genes in vivo is depen-
dent on the pathogen having the capacity to sense its immediate
environment sufficiently to identify contact with the host.
A repeating theme in bacterial virulence is that many,
although not all, mechanisms of virulence are mediated by the
subversion of host biological processes [16]. This involves
specific (physical) interaction between the products of bac-
terial virulence genes and the host molecules that lead to
alteration in host biological functions that serve the purposes
of the pathogen, such as to survive and proliferate. A range of
host cell functions have been shown to be subverted by
bacterial pathogens, including a variety of signalling cascades
ultimately resulting in reorganisation of the cytoskeletal
apparatus during invasion of the host cell, inhibition of
phagocytosis by host immune cells, and either promotion or
inhibition of host cell apoptosis.
A system for classification of mechanisms of virulence is
outlined in Table 1. The remainder of the present review
describes selected mechanisms of virulence in greater depth.
Those examples chosen for further discussion have been
selected either because they illustrate important themes or
principles or because they have particular relevance to
infections that occur in the ICU. Many of the listed examples
of mechanisms have, of necessity, been elucidated using
models in which bacteria interact with host cells, often in cell
culture, rather than with intact animals. The major purpose of
this section is to describe the molecular basis of the
host–pathogen interaction. The biological importance of
these interactions has been established, for some mecha-
nisms, using intact animals – although for some infections the
absence of suitable models of infection precludes this.
Adhesion
Physical attachment of bacteria to host tissues, termed
adhesion, is a critical component of almost all bacteria–host
interactions. Adhesion can be divided into two broad
categories: initial colonisation of the host surface via specific
interactions with host receptors, and intimate association ofPage 3 of 8
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the bacteria with the host cell surface leading to invasion (see
following sections).
The airway epithelium is the first point of contact for Neisseria
meningitidis,  Pseudomonas aeruginosa,  Staphylococcus
aureus and streptococci. These pathogens must overcome a
variety of mechanical impediments to initiate contact with this
epithelium. The airway epithelium consists of a variety of cell
types, including squamous epithelial cells, ciliated and
nonciliated columnar cells, goblet cells and microfold cells.
The goblet cells secrete mucin, which forms a gel-like barrier
covering the cell surface. The beating ciliated cells ensure
constant movement of the mucin across this surface.
Initial contact of bacterial pathogens with the airway
epithelium cells occurs via pili, long hair-like structures that
protrude from the surface of the bacteria and terminate with a
bacterial adhesin that binds to specific cell surface receptors.
Certain types of pili such as the type IV pili of meningococci
and  P. aeurginosa are retracted into the cell once the
receptor is engaged, thus dragging the bacterial cell into
close contact with the surface of the host cell [17]. Although
it has been recently discovered that S. aureus and
streptococci express pili, the role in disease is not known. It
is, however, clear that these pili are unable to undergo retrac-
tion and therefore are apparently permanently extended [18].
Invasion
Intact epithelial surfaces are a highly effective barrier to
invasion by pathogens. A capacity to breach intact epithelial
surfaces is an important characteristic for many specialised
bacterial pathogens [16]. In contrast, some pathogens are
Available online http://ccforum.com/content/12/6/234
Table 1
Classification of bacterial virulence mechanisms
1. Adhesion
￿ Loose adhesion
￿ Intimate adhesion
2. Invasion
￿ Transcellular (uptake across cell membranes using host cell uptake mechanisms, such as phagocytosis and microfold cell sampling or 
pathogen-directed endocytosis)
￿ Intercellular (traversal of an epithelial barrier between epithelial cells)
3. Intracellular survival mechanisms
￿ Within cytoplasm following escape from phagosome or endocytic vesicle
￿ Within an endocytic vesicle via avoidance of phagolysosome formation or autophagocytic pathway
￿ Prevention of host cell apoptosis
4. Extracellular survival mechanisms
￿ Antiphagocytic mechanisms (such as triggering of phagocyte apoptosis, subversion of lysosome fusion with the phagosome, resistance to 
oxygen free radicals)
￿ Serum resistance via preventing complement activation on the bacterial cell surface and inhibition of membrane attack complex insertion 
into the bacterial membrane
5. Nutrient acquisition
￿ Iron acquisition systems
6. Damage host cells and tissues
￿ Cytotoxins
￿ Enzymes that degrade extracellular matrix components
7. Motility
￿ Swimming (for example, flagella)
￿ Twitching motility (for example, type IV pili)
8. Biofilm formation
9. Regulation of virulence
￿ Sense environment and regulate transcription/activation of virulence genes
￿ Sense other bacteria (quorum sensing) and regulate transcription/activation of virulence genesdependent on local defects in the epithelial surface to
achieve invasion, such as occurs with wound infections or
peritonitis secondary to perforation of the intestinal tract.
Most pathogens that have the capacity to cross intact
epithelial surfaces do so by passing through (transcellular),
rather than between (intercellular), the cells of the epithelial
surface. Transcellular uptake is either cell initiated – for
example, by microfold cells that sample and internalise luminal
contents as part of immune surveillance [19] – or pathogen
directed – in which the pathogen subverts host mechanisms,
leading to internalisation of the bacteria. A well-characterised
process of pathogen-initiated transcellular uptake is utilised by
Salmonella enterica. Following tight adherence of the bacteria
to enterocytes, a T3SS is utilised to inoculate bacterial
effector proteins into the host cell cytoplasm. These proteins,
SopE and SopE2, function as GTPases leading to activation
of host protein regulators of the actin cytoskeleton. Activation
of these host proteins, CDC42 and Rac, leads to
rearrangement of actin so that the cell membrane protrudes,
surrounds, and then engulfs the adherent bacteria, delivering
the bacteria across the cell membrane and into the cytoplasm
[20]. Similar mechanisms are possessed by a wide variety of
pathogens, including Yersinia  sp.,  Shigella  sp.,  Escherichia
coli, and P. aeruginosa.
Subversion of phagocytosis to access a
protected intracellular niche
Many important host defence mechanisms, such as comple-
ment and antibodies, act only within extracellular spaces.
Some pathogens possess specialised mechanisms that allow
them to exploit the protection conferred by the intracellular
environment of the host cell. One such mechanism of
accessing the intracellular environment is subversion of
phagocytosis. Normal phagocytosis commences with the
engulfment of the pathogen by neutrophils or macrophages
that bind the bacteria. This results in the rearrangement of the
actin cytoskeletal apparatus to produce pseudopodia that
extend around and engulf the bacteria. An internalised
membrane-bound vesicle containing the bacterium, termed a
phagosome, is ingested and fuses with lysozomes, resulting
in the formation of a phagolysozome. The lysozomes deliver
low acidity, reactive oxygen moieties, proteolytic enzymes,
and antibacterial peptides into the vesicle, leading to the
destruction of the engulfed bacteria [21].
Some intracellular pathogens, such as Legionella pneumo-
phila, Coxiella brunetii, and Brucella abortus, are capable of
arresting the maturation of the phagolysosome [21]. This
prevents delivery of the effector molecules of the lysosome,
resulting in a membrane-bound compartment that supports
bacterial survival and proliferation. Other intracellular patho-
gens, such as Shigella sp. and Listeria sp., have the capacity
to disrupt the phagosome membrane, prior to its maturation,
allowing the bacteria to escape into the cytosol where they
survive and proliferate [21].
For many bacteria the precise mechanism by which normal
phagocytosis is subverted is increasingly well understood.
For example, following phagocytic uptake L. pneumophila
injects multiple effector proteins, many of which are struc-
turally similar to eukaryotic proteins, into the cytosol of the
host cell via the Icm/Dot type IV secretion system. Although
many interactions remain to be elucidated, the type IV
secretion system effector proteins act to recruit host
encoded small GTPases Rab1 and Sar1 to the Legionella-
containing vacuole, thus preventing phagosome maturation
[22-24]. The recruitment of the GTPases to the Legionella-
containing vacuole results in the vacuole acquiring charac-
teristics that are similar to the endoplasmic reticulum [24] to
which lysozomes cannot fuse, thus creating a protected niche
for the bacteria. The lifecycle of L. pneumophila can also
involve existence within water-borne amoeba, with the same
process of avoidance of phagosome maturation mediated by
interaction between effector proteins and highly conserved
eukaryotic proteins that regulate membrane trafficking
occurring in this host [22].
Prevention of phagocytic uptake
Many pathogens lack a specialised apparatus to subvert
phagosomal maturation and use avoidance of phagocytosis
as a necessary strategy for virulence. Bacteria with mecha-
nisms that subvert uptake by neutrophils and macrophages
include Yersinia sp., P. aeruginosa, and enteropathogenic E.
coli [25].  Yersinia sp. utilise a T3SS to directly inoculate
effector proteins into the cytoplasm of host phagocytic cells.
These effector proteins, including YopH, YopE, and YopT,
interact directly with host encoded proteins that regulate
actin polymerisation, thus preventing the cell surface membrane
rearrangements that lead to phagocytic internalisation
[26,27]. Similarly, the T3SS of P. aeruginosa inoculates ExoT
and ExoS into the cytosol of host cells. Although these
pseudomonal effector proteins are unrelated to the Yop
factors, they activate some of the same host targets (the Rho
GTPases RhoA, Rac-1, and Cdc42), resulting in the paralysis
of engulfment by the phagocytic cell [25,28].
Regulation of host cell apoptosis
Several bacterial pathogens possess mechanisms to subvert
host cell apoptosis, usually leading to the apoptotic destruc-
tion of host inflammatory cells. Pathogens that interact with
host cells and induce apoptosis include Salmonella sp.,
Shigella sp., Streptococcus pneumoniae and P. aeruginosa
[29-31]. In contrast, Chlamydia sp. and Mycobacterium
tuberculosis act to inhibit apoptosis following invasion, thus
preserving cells that act as their intracellular niche [29]. The
mechanisms utilised by Salmonella sp. and Shigella sp. to
induce apoptosis of neutrophils have been elucidated in each
pathogen and involve the T3SS effector proteins SipB and
IpaB, respectively. These proteins act in the neutrophil cyto-
sol, binding to and activating host caspase 1, the activation of
which leads to host cell apoptosis. This process is likely to be
important in abrogating the neutrophil-mediated killing of
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Serum resistance
The complement cascade is an essential arm of the innate
immune system as well as an effector of the adaptive immune
system. Over 20 proteins and protein fragments make up the
complement system, including serum proteins, serosal
proteins, and cell membrane receptors that are produced
constitutively and circulate in the blood stream. The activation
of this system by the classical and alternate pathways leads
to the opsonisation of the pathogen with C3b and its
cleavage fragment iC3b. Complement receptors on phago-
cytes bind C3b or C4b and iC3b, resulting in phagocytosis of
the pathogen in the presence or absence of antibodies. If
complement activation continues from C3b to the formation
of C5-convertases C5a and C5b, these molecules act as
chemoattractants that recruit inflammatory cells to sites of
infection. Ultimately the pathway also results in the formation
of the membrane attack complex (MAC) that inserts into the
outer membrane of pathogen, forming pores that eventually
lead to destruction of the bacterial cell. Host surfaces are
protected from complement attack by host encoded
inhibitors such as Factor H and C4b-binding protein. Host
Factor H binds cell surface polyanions such as terminal sialic
acid on glycoproteins, and accelerates the decay of C3b into
inactive iC3b. Similarly C4b-binding protein prevents the
formation of new convertases by proteolytically degrading
C4b [33].
Bacterial pathogens have adopted four main strategies to
overcome the complement cascade: restricting the formation
of C3b and C4b on the bacterial cell surface, the acquisition
of Factor H and C4b-binding protein to their own cell
surfaces to downregulate activation of convertases on the
bacterial cell surface, the inactivation of C5a to prevent
recruitment of inflammatory cells to the site of infection, and
the inhibition of MAC insertion [33]. Resistance to insertion of
the MAC is critically important to the serum resistance that is
a characteristic of many pathogens. Gram-positive cell walls
are intrinsically resistant to insertion of the MAC (Lambris).
Among many Gram-negative organisms, the presence of
smooth lipopolysaccharide results in resistance to the MAC.
The rarity of bacteraemia caused by enteric Gram-negative
organisms with rough lipopolysaccharide reflects the
importance of this mechanism of serum resistance.
Furthermore, other Gram-negative serum-resistant pathogens,
such as N. meningitidis and K1 strains of E. coli that cause
neonatal meningitis, have serum resistance as a conse-
quence of the protection conferred by sialic acid-containing
capsules that prevent penetration of the MAC. In some
instances, pathogens do not rely on one mechanism to
become resistant to complement but use a collage of
strategies. For example, N. meningitidis, in addition to its
sialic acid capsule that restricts MAC insertion, possesses
other mechanisms of serum resistance, including the major
surface glycolipid lipopolysaccharide (lipo-oligosaccharide)
that excludes C4b deposition, whilst surface proteins such as
type IV pili and PorA attract C4b-binding protein, and the
OMP GNA1870 binds Factor H [34]. Similarly, Group B
β-haemolytic streptococci express a sialic acid capsule that
restricts C3b deposition on the bacterial surface, an outer
surface protein (Bac) acts as a filamentous Factor H binding
protein, and C5a is directly inactivated by the bacterial C5a
peptidase [35]. In these examples, it has been shown that
some of these strategies play a more predominant role than
others in the virulence of these organisms. For example, 
C5a peptidase is not expressed by all invasive Group B
β-haemolytic streptococci although it is clear that inflam-
mation in the host is reduced when it is not expressed by the
pathogen [35].
Quorum sensing
Quorum sensing is an interbacterial signalling system that
provides a link between the local density of bacteria and the
regulation of gene expression. The sensing allows a
population of bacteria to coordinate their gene expression in
a manner that is dependent on the number of colocated
bacteria. Quorum sensing is used by some pathogens, most
notably  P. aeruginosa, to coordinate the expression of
virulence genes. This allows populations of bacteria to adopt
virulent behaviour but only when a critical mass of bacteria is
present [36].
The quorum sensing system of P. aeruginosa comprises two
separate but interrelated systems, rhl and las, both of which
utilise (different) acyl homoserine lactones as signal
transducers. The acyl homoserine lactones are secreted into
the local environment with concentrations increasing in
relation to bacterial numbers. Above a threshold intracellular
concentration, the secreted acyl homoserine lactone
molecules passively re-enter the cytosol of the bacteria,
binding to and activating transcriptional regulators – which
results in the expression of a range of genes that contribute
to virulence [36]. Experimental inactivation of the rhl and las
systems results in marked attenuation of pseudomonal
virulence in animal models of burns and pneumonia [36,37].
Biofilm formation
Biofilms are self-assembling, multicellular, communities of
bacteria attached to a surface and enclosed within a self-
secreted exopolysaccharide matrix [38]. Bacteria that are
capable of forming biofilms can switch between a free-living, or
planktonic, form or existing within a biofilm. A mature biofilm is
comprised of micro-colonies of bacteria within an
exopolysaccharide matrix that is interspersed with water-filled
channels that supply nutrients and remove wastes. The exopoly-
saccharide matrix is responsible for the sliminess of biofilms.
Biofilms are particularly resistant to many forms of physical
and chemical insult, including antibiotics. Important patho-
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aureus, coagulase-negative Staphylococci, and P. aerugi-
nosa [38]. In the ICU, biofilms are particularly important for
infection and colonisation of devices such as intravascular
catheters, urinary catheters, endotracheal tubes, and pros-
thetic heart valves.
Bacteria within a biofilm are highly tolerant to antibiotics, even
when planktonic derivatives of a biofilm demonstrate high
degrees of in vitro sensitivity to the same antibiotic. The origin
of biofilm tolerance to antibiotics is multifactorial but includes
reduced penetration of antibiotics into the biofilm matrix and
the presence of metabolically inactive dormant cells [39]. The
functional resistance of biofilm-associated infections to anti-
biotics explains the importance of removal of infected devices
to successful clearance of infection.
Bacterial virulence - evolutionary origin
The mechanisms of bacterial virulence that have been
described represent only a small selection among many
different strategies. Nevertheless, those chosen are represen-
tative and serve to illustrate that bacterial virulence frequently
involves specific interactions, at a molecular level, between
bacterial encoded structures with host molecules that leads
directly to the subversion of host cell functions to provide a
survival advantage for the bacteria. These mechanisms have
presumably developed over hundreds of millions of years of
coexistence of bacterial pathogens and hosts [40]. That
mechanisms of such sophistication have developed reflects
the power of vertical evolutionary change in organisms with
short generation times coupled to the spread of genes that
confer advantage by horizontal genetic exchange.
Clinical implications
The elucidation of the subversion of host mechanisms to
promote bacterial virulence has been of major scientific
interest, reflecting the elegance and sophistication of these
mechanisms. The pathogens that have been most intensively
studied are those that are capable of virulence irrespective of
the presence of defects in local or systemic host immunity.
Many infections that necessitate admission to the ICU occur
in the context of a previously healthy host and involve no
obvious defect in local or systemic immunity. Examples of
these types of infection include overwhelming meningococcal
sepsis and some patients with community-acquired pneu-
monia, urosepsis, and skin and soft tissue infections. Many
patients with infection that leads to ICU admission, however,
possess underlying defects that predispose them to infection,
including systemic factors such as pharmacological immuno-
suppression, malignancy, and diabetes or local defects such
as obstructed or perforated viscus, invasive devices, or
surgical wounds. The majority of nosocomial infections
acquired in the ICU are also heavily influenced by local and
systemic defects in host immunity, particularly the presence
of invasive devices (van der Kooi). While factors such as
capsulation and serum resistance are likely to be critical in
the establishment of nosocomial infection, the importance of
more elaborate mechanisms of bacterial virulence to
infections that occur in this context is less certain. In general,
there has been much less investigation of mechanisms of
virulence in pathogens of clinical relevance to intensive care,
at least in part because of the paucity of characterised and
validated animal models of nosocomial infections. There is
good evidence for the probable importance of mechanisms
such as biofilm formation, quorum sensing, and serum
resistance in many infections of relevance to ICU patients.
The potential value of mechanisms of virulence as a thera-
peutic or prophylactic target is speculative. There is clear
proof-of-principle that therapeutic targeting of the regulation
of a virulence mechanism can prevent disease by a pathogen
[41]. The bacteria responsible for most serious infections,
however, are killed rapidly by antibiotics and it is uncertain
whether a drug that targeted virulence would have any value
as an alternative or supplement to antibiotics. Furthermore,
since mechanisms of virulence are often restricted to a
specific pathogen and there can be redundancy among
mechanisms of virulence in many pathogens, this type of
targeted intervention may have limited clinical utility.
At the present time there is little enthusiasm in industry for the
development of small-molecule drugs that target virulence
mechanisms. This is despite two theoretical attractions to
targeting virulence. Firstly, at least conceptually, there is a
potentially attractive role for drugs that target virulence in the
prevention of ICU-related nosocomial infections. Antibiotics,
which kill commensal as well as pathogenic bacteria indiscri-
minately, result in undesired effects such as selection of
antibiotic-resistant organisms and altered mucosal function.
In contrast, an agent that acted to prevent virulence of a
specific pathogen would leave the commensal flora intact.
Although such agents will be highly specific, effective
pharmacoprophylaxis for important nosocomial pathogens,
such as P. aeruginosa or  S. aureus – for example, by
blockade of quorum sensing – might have clinical utility [42].
The importance of preventing nosocomial infections, by any
means, is only likely to increase in association with worsening
antibiotic resistance. Secondly, some forms of infection that
are clinically important in ICU populations are not amenable
to treatment solely with antibiotics. Research of biofilm-
related infections is particularly active and raises the prospect
of control of device-related infection without the need to
remove the device [43].
Conclusion
The mechanisms by which bacterial pathogens interact with
and subvert host defence mechanisms are being rapidly
defined for a wide range of pathogens. While these
mechanisms are likely to be relevant to infections that
necessitate ICU admission in patients with normal host
defences, however, the relevance of these mechanisms to
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defences remains to be established. While there are
theoretical rationales for the development of agents that
target virulence, particularly for nosocomial pathogens, the
restriction of specific virulence mechanisms to a narrow
range of pathogens may limit utility.
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